Clinical Trial Update: BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for BrEPEM-LH-22017 in older patients with untreated Hodgkin lymphoma (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• BrEPEM-LH-22017

Snippet

Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Conditions: Hodgkin Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN